Maria Liljefors

587 total citations
20 papers, 451 citations indexed

About

Maria Liljefors is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Maria Liljefors has authored 20 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Immunology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Maria Liljefors's work include Immunotherapy and Immune Responses (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and T-cell and B-cell Immunology (5 papers). Maria Liljefors is often cited by papers focused on Immunotherapy and Immune Responses (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and T-cell and B-cell Immunology (5 papers). Maria Liljefors collaborates with scholars based in Sweden, Denmark and France. Maria Liljefors's co-authors include Jan‐Erik Frödin, Håkan Mellstedt, Peter Ragnhammar, Fariba Mozaffari, Jan Fagerberg, Bo Nilsson, Britta Wahrén, J. Shetye, Kristian Hallermalm and Gustav Ullenhag and has published in prestigious journals such as PLoS ONE, Scientific Reports and Annals of the New York Academy of Sciences.

In The Last Decade

Maria Liljefors

20 papers receiving 437 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maria Liljefors Sweden 12 243 224 133 85 50 20 451
Pia M. Challita-Eid United States 10 255 1.0× 279 1.2× 142 1.1× 80 0.9× 26 0.5× 18 556
A. Lage Cuba 10 195 0.8× 264 1.2× 168 1.3× 109 1.3× 24 0.5× 31 495
Lestat R. Ali United States 12 355 1.5× 332 1.5× 177 1.3× 136 1.6× 28 0.6× 17 595
Korina G. Veenstra United States 6 317 1.3× 216 1.0× 139 1.0× 38 0.4× 26 0.5× 8 484
Jennifer B. Jacob United States 13 293 1.2× 159 0.7× 194 1.5× 105 1.2× 17 0.3× 21 500
Yongxiang Yan China 8 332 1.4× 356 1.6× 203 1.5× 70 0.8× 37 0.7× 12 619
Alois Walder Austria 4 228 0.9× 166 0.7× 86 0.6× 54 0.6× 49 1.0× 6 377
Aaron T. Alpar United States 10 232 1.0× 190 0.8× 166 1.2× 53 0.6× 23 0.5× 18 454
Yanhua Yuan China 12 262 1.1× 231 1.0× 276 2.1× 36 0.4× 15 0.3× 30 508
Fariba Mozaffari Sweden 14 332 1.4× 306 1.4× 146 1.1× 30 0.4× 31 0.6× 22 566

Countries citing papers authored by Maria Liljefors

Since Specialization
Citations

This map shows the geographic impact of Maria Liljefors's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Liljefors with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Liljefors more than expected).

Fields of papers citing papers by Maria Liljefors

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Liljefors. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Liljefors. The network helps show where Maria Liljefors may publish in the future.

Co-authorship network of co-authors of Maria Liljefors

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Liljefors. A scholar is included among the top collaborators of Maria Liljefors based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Liljefors. Maria Liljefors is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nissen, Neel I., Rasmus S. Pedersen, Mogens K. Boisen, et al.. (2023). Levels of type XVII collagen (BP180) ectodomain are elevated in circulation from patients with multiple cancer types and is prognostic for patients with metastatic colorectal cancer. BMC Cancer. 23(1). 949–949. 10 indexed citations
2.
Linder, Stefan, Maximilian Kordes, Maria Liljefors, et al.. (2022). Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia – A comparison with pancreatic ductal adenocarcinoma. Pancreatology. 22(5). 598–607. 7 indexed citations
3.
Nissen, Neel I., S.N. Kehlet, Mogens K. Boisen, et al.. (2021). Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab. Scientific Reports. 11(1). 865–865. 22 indexed citations
4.
Ullenhag, Gustav, et al.. (2017). Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE. 12(1). e0169736–e0169736. 14 indexed citations
5.
Mozaffari, Fariba, et al.. (2017). DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. 2(2). 1 indexed citations
6.
Ullenhag, Gustav, Eva Rossmann, & Maria Liljefors. (2015). A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE. 10(4). e0121197–e0121197. 7 indexed citations
7.
Mozaffari, Fariba, et al.. (2014). Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. International Journal of Oncology. 45(3). 1293–1303. 59 indexed citations
8.
Magnusson, Carl, Mohammad Hojjat‐Farsangi, Szilvia Mosolits, et al.. (2012). Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein. Journal of Clinical Immunology. 32(4). 855–865. 28 indexed citations
9.
Mozaffari, Fariba, et al.. (2010). A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine. 29(39). 6817–6822. 47 indexed citations
10.
Liljefors, Maria, Bo Nilsson, Håkan Mellstedt, & Jan‐Erik Frödin. (2007). Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity. Cancer Immunology Immunotherapy. 57(3). 379–388. 10 indexed citations
11.
Liljefors, Maria, Bo Nilsson, Jan Fagerberg, et al.. (2005). Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. International Journal of Oncology. 26(6). 1581–9. 23 indexed citations
12.
Liljefors, Maria, Peter Ragnhammar, Bo Nilsson, et al.. (2004). Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with α-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. International Journal of Oncology. 25(3). 703–11. 6 indexed citations
13.
Shetye, J., Maria Liljefors, Stefan O. Emdin, et al.. (2004). Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients.. PubMed. 24(4). 2375–83. 11 indexed citations
14.
Liljefors, Maria, et al.. (2003). Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A. International Journal of Cancer. 105(5). 717–723. 50 indexed citations
15.
Frödin, Jan‐Erik, et al.. (2002). MAb17-1A and Cytokines for the Treatment of Patients with Colorectal Carcinoma. PubMed. 21(2). 99–101. 7 indexed citations
16.
Mellstedt, Håkan, Jan Fagerberg, Jan‐Erik Frödin, et al.. (2000). Ga733/EpCAM as a Target for Passive and Active Specific Immunotherapy in Patients with Colorectal Carcinoma. Annals of the New York Academy of Sciences. 910(1). 254–262. 25 indexed citations
17.
Ragnhammar, Peter, Jan Fagerberg, Jan‐Erik Frödin, et al.. (1999). Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunology Immunotherapy. 48(8). 463–470. 16 indexed citations
18.
Mellstedt, Håkan, Jan Fagerberg, Jan‐Erik Frödin, et al.. (1999). Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Current Opinion in Hematology. 6(3). 169–169. 40 indexed citations
19.
Shetye, J., Peter Ragnhammar, Maria Liljefors, et al.. (1998). Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.. PubMed. 4(8). 1921–9. 20 indexed citations
20.
Ragnhammar, Peter, et al.. (1996). Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunology Immunotherapy. 42(2). 81–87. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pia M. Challita-Eid Breakdown of academic impact, for papers by A. Lage Breakdown of academic impact, for papers by Lestat R. Ali Breakdown of academic impact, for papers by Korina G. Veenstra Breakdown of academic impact, for papers by Jennifer B. Jacob Breakdown of academic impact, for papers by Yongxiang Yan Breakdown of academic impact, for papers by Alois Walder Breakdown of academic impact, for papers by Aaron T. Alpar Breakdown of academic impact, for papers by Yanhua Yuan Breakdown of academic impact, for papers by Fariba Mozaffari
Rankless by CCL
2026